Premium
Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain
Author(s) -
Meyer Michael D.
Publication year - 2006
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20099
Subject(s) - neuropathic pain , nicotinic agonist , nicotinic acetylcholine receptor , neuroscience , acetylcholine receptor , nociception , acetylcholine , pharmacology , medicine , chronic pain , mechanism of action , receptor , psychology , chemistry , biochemistry , in vitro
Neuronal nicotinic acetylcholine receptor (nAChR) agonists have been demonstrated to exhibit antinociceptive, antihyperalgesic, and antiallodynic effects across a range of preclinical models of pain. Yet, to date, no drugs have been successfully developed and approved for the treatment of pain from this pharmacological class. In this overview, the mechanism and site of action of nAChR agonists in models of neuropathic pain, as well as the current status and future prospects for the development of drugs from this class for the treatment of neuropathic pain, will be discussed. Drug Dev. Res. 67:355–359, 2006. © 2006 Wiley‐Liss, Inc.